Abstract

Background: According to current data, an effective Ebola virus vaccine should induce both humoral and T-cell immunity. In this work, we focused our efforts on methods for delivering artificial T-cell immunogen in the form of a DNA vaccine, using generation 4 polyamidoamine dendrimers (PAMAM G4) and a polyglucin:spermidine conjugate (PG). Methods: Optimal conditions were selected for obtaining complexes of previously developed DNA vaccines with cationic polymers. The sizes, mobility and surface charge of the complexes with PG and PAMAM 4G have been determined. The immunogenicity of the obtained vaccine constructs was investigated in BALB/c mice. Results: It was shown that packaging of DNA vaccine constructs both in the PG envelope and the PAMAM 4G envelope results in an increase in their immunogenicity as compared with the group of mice immunized with the of vector plasmid pcDNA3.1 (a negative control). The highest T-cell responses were shown in mice immunized with complexes of DNA vaccines with PG and these responses significantly exceeded those in the groups of animals immunized with both the combination of naked DNAs and the combination DNAs coated with PAMAM 4G. In the group of animals immunized with complexes of the DNA vaccines with PAMAM 4G, no statistical differences were found in the ability to induce T-cell responses, as compared with the group of mice immunized with the combination of naked DNAs. Conclusions: The PG conjugate can be considered as a promising and safe means to deliver DNA-based vaccines. The use of PAMAM requires further optimization.

Highlights

  • The Ebola virus (EBOV) causes acute severe illness that often results in lethal outcomes in the absence of therapy

  • The immunogenicity of the resulting vaccine constructs was evaluated in BALB/c mice

  • To increase the immunogenicity of DNA vaccines, the plasmids pEV.cytotoxic T-lymphocytes (CTLs) and pEV.Th were complexed with two types of polycationic polymers: cationic polyglucin and PAMAN 4G (Figure 3)

Read more

Summary

Introduction

The Ebola virus (EBOV) causes acute severe illness that often results in lethal outcomes in the absence of therapy. The EBOV fever is one of the most dangerous viral diseases known to humanity. Most vaccines under development are based on the use of the surface glycoprotein of the EBOV, since it is believed that the humoral immune response plays a major role in the formation of protective immunity against the pathogen. An effective Ebola virus vaccine should induce both humoral and T-cell immunity. T-cell immunogen in the form of a DNA vaccine, using generation 4 polyamidoamine dendrimers (PAMAM G4) and a polyglucin:spermidine conjugate (PG). Methods: Optimal conditions were selected for obtaining complexes of previously developed DNA vaccines with cationic polymers. The immunogenicity of the obtained vaccine constructs was investigated in BALB/c mice

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call